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WHAT’S KNOWN ON THIS SUBJECT 
The iodide recommendation for preterm enteral nutrition is 30-40μg/kg/day but 1μg/kg/day 
for parental nutrition.  Iodide is needed to produce thyroid hormones, which are essential for 
normal brain development.  Observational studies report associations between low postnatal 
thyroid hormones and compromised neurodevelopment.      
WHAT THIS STUDY ADDS 
The neutral results do not indicate that the iodide content of parenteral nutrition should 
routinely be increased from the current level to match the enteral level. This evidence may 
not apply to preterm infants on primarily parental nutrition over prolonged periods. 
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ABSTRACT 
Background The recommendation for enteral iodide intake for preterm infants is 30–40 
μg/kg/day and 1μg/kg/day for parenteral intake.  Preterm infants are vulnerable to iodide 
insufficiency and thyroid dysfunction. The hypothesis tested whether, compared to placebo, 
iodide supplementation of preterm infants improves neurodevelopment. 
 
Methods A randomized controlled trial of iodide supplementation versus placebo in infants 
<31 weeks’ gestation. Trial solutions (sodium iodide or sodium chloride; dose 30μg/kg/day) 
were given within 42 hours of birth to the equivalent of 34 weeks’ gestation. The only 
exclusion criterion was maternal iodide exposure during pregnancy or delivery. Whole blood 
levels of thyroxine, thyrotropin and thyroid binding globulin were measured on four specific 
postnatal days. The primary outcome was neurodevelopmental status at two years’ of age, 
measured using the Bayley-III scales. The primary analyses are by intention-to-treat and data 
are presented also for survivors. 
 
Results 1,273 infants (637 intervention, 636 placebo) were recruited from 21 UK neonatal 
units. 131 infants died, and neurodevelopmental assessments were undertaken in 498 iodide 
and 499 placebo supplemented infants. There were no significant differences between the 
intervention and placebo groups in the primary outcome: mean difference Cognitive score, -
0.34, 95% confidence interval (CI) -2.57 to 1.89; Motor composite score, 0.21, 95% CI -2.23 to 
2.65; Language composite score, -0.05, 95%CI -2.48 to 2.39. There was evidence of weak 
interaction between iodide supplementation and hypothyroxinemic status in the Language 
composite score and one subtest score.   
  
Conclusions Overall iodide supplementation provided no benefit to neurodevelopment 
measured at 2 years of age. 
 
Trial Registration and Funding CTA No. 21584/0251/001, and registration No. 
NCT00638092. Funded by MRC and managed by NIHR on behalf of the MRC-NIHR 
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INTRODUCTION 
Thyroid hormone is essential for normal brain development in-utero and for the first two years of 
life. Brain damage through deficiency of thyroxine (T4) is irreversible. Congenital 
hypothyroidism is the most extreme form of thyroid hormone deficiency. A milder form of 
deficiency, transient hypothyroxinemia, is characterized by low or normal levels of thyrotropin 
(TSH) and low T4 levels. Transient hypothyroxinemia is common in preterm infants,1  its 
etiology is multifactorial2-6 and includes iodide deficiency.7,8  The European guideline for 
preterm neonatal enteral iodide intake is 11–55μg/kg/day;9 although, evidence from balance 
studies suggests that the intake for healthy preterm infants should be a minimum of 30–
40μg/kg/day.7  The guideline for parenteral nutrition is 1μg/kg/day.10,11  
The iodide requirement of extreme preterm infants is complex and difficult to assess. Neonates 
have very small iodine reserves,12 are vulnerable to iodine toxicity,13 and their immature 
physiology can demand higher levels of some nutrients, especially ions, relative to the term 
neonate.14 Extreme preterm infants are fed parenterally until their clinical condition improves, 
when the contribution of parenteral to formula/breast milk gradually decreases. Iodide balance 
studies of preterm infants show that they are in negative iodide balance7,8 until their intake of 
nutrition is primarily enteral. Iodine is an essential component of thyroid hormones and because 
the preterm infant has small iodide reserves within the thyroid gland,12 it is essential that daily 
nutrients provide sufficient iodide to support T4 production.   
Although transient hypothyroxinemia was formerly thought of as clinically harmless, recent 
studies show associations with neurodevelopmental compromise.15-20  Infants with transient 
hypothyroxinemia perform less well on developmental tests and this compromise persists into at 
least late childhood.18 These children are predicted to perform less well at school, which has 
consequences for their lifetime achievements and well-being. The link between suboptimal 
neurodevelopment and the early iodide status of preterm infants is not well known. It is also 
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unknown whether iodide supplementation can confer a benefit to later outcome. Our aim was to 
determine whether iodine supplementation leads to improved neurodevelopmental outcome in 
extreme preterm infants at 2 years of age. 
PATIENTS AND METHODS 
I2S2 was a UK, randomized, placebo-controlled trial.21 The trial was approved by Tayside 
Committee on Medical Research Ethics (08/S0501/31), Medicines and Healthcare products 
Regulatory Agency (CTA No. 21584/0251/001), and registered with clinical trials 
(NCT00638092) and EudraCT, No. 2008-001024-31. Written informed consent was obtained 
from the infants’ parents.  
Infants were eligible if they were <42 hours old, born <31 weeks’ gestation in one of the trial 
recruiting hospitals, and had a realistic prospect of survival. The only exclusion criterion was 
maternal exposure to iodide during pregnancy or delivery (e.g. the use of topical iodides for skin 
antisepsis prior to epidural/caesarean section/other surgery, or from exposure to iodinated 
contrast media. Women absorbing iodide from multi-vitamins or from their habitual diet were 
eligible for enrollment.)  
RANDOMIZATION AND MASKING 
Eligible infants were randomized to intervention or placebo (with roughly equal probability) 
using a secure website with 24/7 telephone back-up.21 The randomization program used a 
bespoke minimisation algorithm to ensure balance across hospitals on gender and gestational 
age (by individual week from 22-25 weeks, 26-27 weeks, and 28-30 weeks (Supplementary 
Table 0, Appendix).  Infants from multiple births were randomized individually. Masking 
ensured that the research team, trial statistician, parents, neonatal staff and pharmacy were 
blind to the content of the trial solutions.  
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PROCEDURES 
Mother/infants were recruited by I2S2 trained staff. Trial solutions were prescribed by 
medical staff following I2S2 guidance sheets. Infants received either the intervention (sodium 
iodide diluted to an iodide content of 75μg/ml) or placebo (sodium chloride diluted to a 
chloride content of 75μg/ml). The packaging and visual appearance of trial solutions were 
identical and the solutions could be given either parenterally or enterally. (Enteral absorption 
of iodide is almost complete, thus the parenteral and enteral intakes should be the same.) The 
dose was 30μg/kg/day, given daily from randomization until the equivalent of 34 weeks’ 
gestational age (had the fetus remained in-utero referred to hereafter as equivalent gestational 
age).   
Infant blood was collected on blood spot cards at postnatal days 7, 14, 28, and at 34 weeks’ 
equivalent gestational age, ±1 day. Cards were sent to the Amsterdam Neonatal Screening 
Laboratory for estimation of T4, TSH and TBG (thyroid-binding-globulin). Detailed clinical data 
were collected throughout the study by trial staff.21 Drug prescriptions, nutritional data, and level 
of nursing care (as an indicator of illness severity,6 Supplementary Table 1, Appendix) were 
recorded on the days when trial blood samples were taken. Data were collected from study entry 
until 36 weeks’ equivalent gestational age, including all inter-unit transfers (or from discharge 
home/death if these occurred before 36 weeks).  Medical and social information for the period 
between hospital discharge and the two year follow-up was recorded on a form, completed by 
the person bringing the child to the appointment. Infants were assessed using the Bayley-III 
Scales of Infant and Toddler Development22 at two years of age corrected for prematurity (±1 
month). The Bayley-III provides information on three domains (Cognitive, Motor composite and 
Language composite scales, each with a population mean of 100 and standard deviation (SD) of 
15) and four subtest scales (Expressive Communication, Receptive Communication, Fine Motor 
and Gross Motor scales, each with a mean of 10 and SD of 3). Infants were assessed using trial 
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personnel specifically trained to use the Bayley-III and random performances were video-
recorded and audited. The setting for the interventional phase was the neonatal unit and follow-
up at two years was undertaken in a hospital close to the infants’ home.    
There were no restrictions on medications or treatments permitted during the trial, including 
Levo-thyroxine if prescribed.  Infants were immediately withdrawn from receiving trial solutions 
if they were exposed to topical iodide containing antiseptics or if iodinated contrast media was 
given. Such infants were monitored locally for the biochemical features of iodine toxicity on 
thyroid dysfunction. These infants were included in all other aspects of the trial, including the 
two-year follow-up.   
TRIAL OUTCOMES 
The primary outcome was neurodevelopmental status defined by the three domains of the 
Bayley-III at two years of age corrected for prematurity.  Secondary outcomes were: the four 
subtests of the Bayley-III; Bayley-III analysed as a dichotomous outcome (death or a Bayley-III 
score <85 in any of the main domains versus a Bayley-III score 85+); levels of T4, TSH and 
TBG on postnatal days 7, 14, 28 and 34 weeks’ equivalent gestational age (±1 day); various 
measures of neonatal type and severity of illness;21 and prescribed drug usage.21  
STATISTICAL ANALYSIS 
To detect a difference in mean Bayley-III score of 6 units (assuming a SD of 15) and taking 
into account anticipated mortality, with 90% power and a two-sided 5% level of significance, 
a target sample size of 1400 infants was required (Section 2, Appendix).21 Primary outcome 
analyses were by intention-to-treat. Outcomes were compared for all infants allocated to 
intervention or placebo, regardless of whether, or for how long, they received trial solutions.   
Baseline characteristics were described by randomization allocation, using numbers with 
percentages for binary and categorical variables, and means and SD for continuous data. For 
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the three main domains of the Bayley-III, the difference in mean score between the iodide 
and placebo groups was assessed with the independent samples T test, using a 5% 2-sided 
significance level. No adjustment for multiple testing was planned, despite the multiplicity 
of primary outcome measures. If, for example, the results for each of the three main domains 
of the Bayley-III had been statistically significant, clinicians and parents alike would have 
assumed that the replication of effect was corroborating evidence of a genuine treatment 
effect. Therefore ‘penalising’ these effects statistically would be counter-intuitive. Likewise, 
if only one of the domains had been statistically significant, our interpretation would have 
been cautious.   
The minimum Bayley-III score possible for each domain was assigned to deaths, and to 
infants too disabled to make assessment meaningful. This is contrary to the published 
protocol,21 which referred only to deaths, and stated that 55 would be assigned to the main 
domains. However, analysis of preliminary data, blinded to allocation, showed that 8% of 
surviving infants scored lower than the arbitrary cut-off of 55 we had proposed, hence our 
decision to use the value at the bottom of the scale. The primary outcomes were also 
analysed for survivors only, in order to give a fair representation of the average ability of 
assessable children. (For further details about imputation of missing primary outcomes see 
Section 2, Appendix.)  Secondary outcomes analyses were performed in survivors, although 
Bayley-III subtest scores are shown also for the intention-to-treat population. Comparative 
analyses used the odds ratio (OR) plus 99% confidence interval (CI) for 
dichotomous/categorical outcomes, or the mean difference (plus 99% CI) for normally 
distributed continuous outcomes.   
Pre-specified sub-group analyses were performed using the F test for interaction for selected 
baseline (i.e. gestational age ≤25, 26-27, 28-30 weeks and maternal thyroid disease status) and 
other characteristics (the level of nursing care as a proxy for illness severity and infant 
  Page | 10 
 
thyroxinemic status). Infants were classified as hypothyroxinemic if they had a T4 level at or 
below the 10th percentile, corrected to gestational age subgroup (i.e. ≤25, 26-27, 28-30 weeks) 
on postnatal days 7, 14 or 28; the remainder of infants were classified as euthyroid. 
RESULTS 
Between March 2010 and December 2012, 1275 infants were enrolled from 21 hospitals. Two 
infants were randomized in error and 14 parents withdrew consent for their infant’s data to be 
used (Figure 1). Bayley-III assessments were available for 498/631 (79%) iodide and 499/628 
(79%) placebo supplemented infants (Figure 1). Limited follow-up data were available for an 
additional 59/631 (9%) iodide and 48/628 (8%) placebo supplemented infants.  At baseline, 
infant/maternal characteristics were very similar (Table 1).  
Sixty-five (65/631, 10%) infants from the iodide group and 66 (66/628, 11%) infants from the 
placebo group died between randomization and the two year follow-up. The main causes of 
death in the intervention phase were necrotizing enterocolitis (31% in each group), followed by 
infection (iodide group 23%, placebo 20%) (Supplementary Table 2, Appendix).  During the 
neonatal period, 11 infants were treated with Levo-thyroxine for variable durations and variable 
dosages (9 in the iodide arm, 2 in the placebo) and received a working clinical diagnosis of 
hypothyroidism.   At two years of age, 13 infants (7 from the original 11, and 6 additional 
infants) were receiving Levothyroxine (8 iodide and 5 placebo); no infant was reported to have 
thyroid toxicity. 
OUTCOMES 
There was no significant difference between groups in the main domains of the Bayley-III: mean 
difference in Cognitive score, -0.34, 95% CI -2.57 to 1.89; in Motor composite score, 0.21, 95% 
CI -2.23 to 2.65; and in Language composite score, -0.05, 95% CI -2.48 to 2.39 (Table 2). There 
were no differences when the analyses were repeated for survivors, either unadjusted or adjusted 
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(Supplementary Table 3a-e, Appendix). Overall, the frequency of postnatal conditions was 
similar between the groups. The numbers of infants at each level of nursing care, the amount of 
parenteral nutrition (as a percentage of the total nutrition) at each postnatal measurement day, 
and the prescribed drug usage was the same in the iodide and placebo supplemented groups 
(Table 2, Supplementary Table 4, Appendix). 
There were no significant differences between levels of T4 or TBG (Figure 2, Supplementary 
Figure 1, Appendix). Levels of TSH were generally slightly higher in the iodide arm, with 
significant differences evident at postnatal days 7 and 14 (Figure 2).  
PRE-SPECIFIED SUB-GROUP ANALYSIS 
The differences in mean Bayley-III scores between the iodide and placebo groups did not differ 
appreciably by gestational age-group or maternal thyroid disease status (Supplementary Figure 
2); nor by neonatal illness, which was approximated by using the level of nursing care 
(Supplementary Figures 3a and b, Appendix).  For the hypothyroxinemic subgroup (n=288) there 
was weak evidence of a treatment effect, which resulted in treated hypothyroxinemic infants 
having similar Bayley-III scores to euthyroid infants (Supplementary Table 5, Appendix). A test 
of interaction between the hypothyroxinemic and euthyroid groups was significant at the 5% 
level for the Language Composite Score and its subtest score Receptive Communication (Figure 
3). 
ADVERSE EVENTS 
There were no SUSARs reported during the trial. Sixty adverse events were reported for the 
iodide group and 28 for the placebo group. Because some UK newborn screening laboratories 
instigate follow-up tests at TSH levels ≥6mU/l, we classified this level as an adverse event to 
ensure that these infants were investigated quickly by the local unit. The highest TSH level 
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recorded was an isolated value of 34 mU/L; such mildly raised TSHs were not considered 
clinically as an adverse event (Supplementary Table 6, Appendix). 
DISCUSSION 
The evidence from this large pragmatic trial shows no overall benefit of iodide 
supplementation on neurodevelopment, measured at two years, for preterm infants. The 
iodide supplemented group had slightly higher levels of TSH (but not T4 or TBG) than the 
placebo group. The trial shows no adverse consequences associated with iodide 
supplementation at 30μg/kg/day.   
The results of the trial were unexpected and do not agree with the evidence from 
observational studies. The impetus for this trial was the accumulating evidence from 
observational studies that hypothyroxinemia is associated with compromised 
neurodevelopment.15-20 In response to this evidence, some researchers explored the use of 
treatment with thyroxine23,24 but there were insufficient data to determine whether treatment 
was beneficial. Only one study of thyroxine supplementation in preterm infants included 
long-term neurodevelopmental outcome and the results were equivocal.23 In that study, 
infants receiving thyroxine supplementation (compared to placebo) scored 18 points higher 
aged two years on the Bayley-II Cognitive component, but only if they were <27 weeks 
gestation; supplemented infants born ≥27 weeks scored 10 points lower than non-
supplemented infants. Subsequent follow-up at 5.725 and 10 years26 confirmed these findings. 
Despite the equivocal results, a recent survey indicated that clinical treatment with thyroxine 
has increased 2.6 fold in neonates born <27 weeks’ gestation.27 Continuing clinical interest in 
hypothyroxinemia led to a phase 1 placebo-controlled trial of thyroxine with triiodothyronine 
therapy.24 That trial showed changes in T4 with continuous supplement of low-dose 
thyroxine over 42 days, but no benefit of supplementation at three years of age in Bayley-III 
Cognitive score, albeit the study included very few infants.28   In our trial the iodide arm 
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showed no difference in Bayley-III scores between infants classified as hypothyroxinemic 
and euthyroid, whereas in the placebo arm, the hypothyroxinemic group performed worse on 
the Bayley-III than the euthyroid group, especially in the language domain. This result 
suggests that hypothyroxinemia may not simply be an epiphenomenon of non-thyroidal 
illness. The results also suggest that iodide supplementation alone, at 30μg/kg/day, without 
the addition of T4 replacement therapy, can mitigate the adverse consequences of 
hypothyroxinemia.  This is important because T4 replacement therapy may be harmful if it is 
given to infants who do not require it.23   
Explanation of the neutral impact of iodide supplementation that we observe is hindered by 
the lack of iodide balance data, especially urinary iodide excretion. We considered 
monitoring urinary iodide during the active phase of the trial but concluded that the 
collection, storage, transport and analysis of these data would have been prohibitively costly.  
Instead, we relied upon the evidence base, which suggests that: preterm infants are vulnerable 
to iodide deficiency while on parenteral nutrition,7,8 breast and formula milk provide highly 
variable amounts of iodide,29 drugs and supplements typically given to neonates contain 
miniscule amounts of iodide,8 and the UK population is mildly iodide deficient,30,31 which 
exaggerates thyroid dysfunction.  
The neutral effect of this trial has at least three possible explanations: first, the placebo 
infants received iodide from hitherto unknown iodine sources; second, the level of iodide 
supplementation was too low; and thirdly the Bayley-III is insufficiently sensitive. We do not 
believe that the infants in the placebo group were exposed to additional iodide. There are only 
two main sources of extraneous iodide that neonates are routinely exposed: topical iodide 
containing skin cleansers and variable quantities of free iodide from exposure to iodinated 
contrast media.32 Any infant exposed to these sources during the I2S2 trial was immediately 
withdrawn from trial solutions.  A study in 201233 reported that parenteral nutrition contained 
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almost no iodine and, with no evidence to the contrary, 1-3µg/kg/day8 remains the best 
estimate of likely intake of the placebo group. The recommended level of iodide intake of 30-
40µg/kg/day for preterm infants is based on balance data for healthy preterm infants at 
around one month of age.7 It is conceivable that the trial supplement of 30µg/kg/day is too 
low an amount for sick, preterm neonates receiving parenteral nutrition, whose immature 
physiology may require higher amounts of nutrients relative to the term infant. The extra 
nutrient requirement of the extreme preterm infant has already been shown for other ions, 
where the fractional urinary excretion is high in the most extreme preterm infants, but with 
maturation of the kidney this declines.14 It is also possible that 30µg/kg/day is too low for a 
mild-to-moderately iodine deficient population such as the UK.  Future studies, such as the 
meticulous iodine balance study in term infants by Dold et al34, are needed which examine 
the physiology of iodide metabolism in the developing fetus and preterm infant. Finally, the 
use of the Bayley-III scales as the primary outcome may have contributed to the neutral 
findings. The Bayley-III is a test of global neurodevelopment and it is possible that more 
targeted developmental tests incorporating, for example, visual acuity or autobiographical 
memory performance35 may, in the future, identify differences between the groups.  
Although it is not normally appropriate to investigate sub-group variables that could be 
affected by the trial intervention, we felt it was important to do so on this occasion and 
specified a priori and in our statistical analysis plan our intention. The only known human 
role for iodine is for the production of thyroid hormones and we hypothesized that the iodide 
intervention (but not the placebo) would positively affect the Bayley score via the 
intermediary of (increased) thyroid hormone with a concomitant decrease in the incidence of 
hypothyroxinemia. There is no evidence or plausible reason why iodide would have a direct 
or independent effect on the Bayley Score, and other factors which would contribute an 
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independent effect on the Bayley score would be equally distributed between the arms of the 
trial due to random allocation. Thus the typical confounders of interpretation are mitigated.   
 
This trial has three findings.  Iodide supplementation to all infants born <31 weeks’ gestation 
confers no benefit to neurodevelopment measured by the Bayley-III scales at 2 years of age. 
Giving iodide at 30μg/kg/day was associated with no adverse consequences.  Finally, there is 
only weak evidence that the sub-group of hypothyroxinemic infants gained benefit from 
iodide supplementation in one of three main Bayley-III domains. The gain was small and the 
clinical relevance of a gain of this magnitude is uncertain. But, if transient hypothyroxinemia 
is considered an important clinical entity, iodide supplementation of infants with low T4 
levels may provide a pragmatic solution to mitigating the condition. The alternative is to 
supplement only those infants who are hypothyroxinemic; however, identifying infants with 
low T4 levels contemporaneously remains challenging.36   
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Figure 1: Trial profile 
Figure 2: Differences in mean levels of T4 and log TSH between iodide and placebo groups 
by gestation at delivery and day of blood sampling  
Figure 3: Differences in mean Bayley-III scores in survivors between iodide and placebo 
groups by infants’ thyroid status 
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Centre, Nottingham; Sue Hallett, Royal Berkshire Hospital, Reading; Julie Cook, Jessop Wing, Sheffield; Olwyn Major, 
Sunderland Royal Hospital; Avril McManus, Wishaw General Hospital. 
Trial Steering Committee Independent members: Jane Norman (Chair) and James Boardman, University of Edinburgh; 
Joanne Rovet, University of Toronto; Fiona Douglas, University of Dundee; Sam Richmond*, Sunderland Royal Hospital; 
Morag Campbell, NHS Greater Glasgow. Non-independent members: Fiona Williams, Robert Hume, University of Dundee; 
Edmund Juszczak, University of Oxford; Peter Brocklehurst, University College London. Observers: Ursula Bowler, 
Kayleigh Stanbury (née Morgan), University of Oxford.  
Data Monitoring Committee: The Data Monitoring Committee: Henry Halliday (Chair), Belfast; Christopher Kelnar and 
Gordon Murray, University of Edinburgh; Simon Ogston, University of Dundee. 
* Very sadly Sam Richmond passed away during the trial on 10th March 2013.  
NHS Staff in receiving hospitals In addition to the recruiting hospitals, a great many hospitals and NHS staff received I2S2 
trial infants for temporary or permanent continuing care. Their help was invaluable and contributed appreciably to the 
smooth running and success of the trial.  
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Maternal age at delivery – yr (mean ±SD) 
  
29.3 (±6.4) 29.4 (±6.5) 
Maternal thyroid disease concurrent with pregnancy N (%)  22 (4) 
 
 19 (3) 
 
Maternal steroids given for prevention of RDSB  N (%)  586 (93) 
 
 569 (91) 
 
Maternal steroids given for reasons other than RDSB N (%)  40 (6) 
 
 34 (5) 
 









Analgesia given during delivery N (%)  None given 
(women may have more than Entonox (nitrous oxide) 
one type of pain relief) General anaesthesia 
 Epidural/spinal block 
 Opioid 







 52 (8) 
 234 (37) 
 77 (12) 
 260 (41) 
 115 (18) 
32 (5) 
Mode of delivery N (%)  
 Spontaneous cephalic vaginal 
 Vaginal breech 
 Instrumental cephalic vaginal 
 Elective caesarean  








 237 (38) 
 69 (11) 
 14 (2) 
 33 (5) 
275 (44) 
Region of birth N (%) Scotland 
  North East England 
 Remainder England 





















Main cause of preterm birth N (%) 
 Pre-labour rupture of membranes (PROM) 
 Preterm labour without PROM 
 Antepartum haemorrhage (APH) 
 Pregnancy induced hypertension ± APH 
 Other maternal illness 
 Poor fetal growth   
































Gestational age – wk (mean ±SD) 
  
27.4 (±2.0)  27.4 (±2.0)  
Birth weight – g (mean ±SD) 
  
1,055 g (±308) 
 
1,053 g (±309) 
 
Apgar score at 5 mins (mean ±SD) 
  
7.8 (±1.8) 7.8 (±1.8) 




A 8 infants from the placebo group and 6 infants from the iodide group were withdrawn from the trial by their parents 
who would not allow their data to be used (see Figure 1). 
B  RDS denotes Respiratory Distress Syndrome  
C The majority of other is codeine/paracetamol (iodide 19/25, placebo 22/32) 
 Percentages only add to 100% when there are no missing data.   
 
There were no significant differences between the groups for any variables. SD denotes standard deviation  
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TABLE 2 Primary and Secondary Outcomes   





(Iodide – placebo) 
95% CI (P value) 
Primary outcomes (mean ± SD) (intention-to-treat population)A 
Bayley-III Cognitive score 88.9 ± 19.2 
Bayley-III Motor composite score 88.2 ± 21.0 
Bayley-III Language composite score 85.1 ± 21.7 
  
 89.2 ± 19.5 
 88.0 ± 21.6 






 -2.57 to 1.89 (0.77) 
 -2.23 to 2.65 (0.87) 
 -2.48 to 2.39 (0.97) 
Secondary outcomes Bayley-III subtests (mean ± SD) (intention-to-treat population)B 
 Receptive Communication 7.51 ± 3.80 7.46 ± 3.77 0.05 
Expressive Communication 7.31 ± 4.06 7.34 ± 4.06 -0.02 
Fine Motor 8.86 ± 3.99 8.72 ± 4.13 0.15 
 Gross Motor 7.07 ± 3.61 7.16 ± 3.68 -0.09 
 99% CI  
 -0.51 to 0.61  
 -0.62 to 0.57 
 -0.47 to 0.76  
 -0.63 to 0.45  
Low score in any main Bayley domain (i.e. Cognitive, Motor, Language) N (%) Odds ratio (99% CI) 
(intention-to-treat population)A 
 ≥ 85 305.7 (48) 319.6 (51) 1.10 (0.82 to 1.49) 
 <85 (or death) 325.3 (52)  308.4 (49) 
Postnatal infant conditions N (%) 
(survivors only) 
Respiratory distress syndrome 
Chronic lung disease 
Persistent ductus arteriosus 
Necrotizing enterocolitis 
Hyperbilirubinemia 
Infants with ≥ 1 acquired infections 
Cerebral pathology closest to 34 weeks 
 Porencephalic cyst 
 Cystic periventricular leukomalacia 
 Ventriculomegaly 
 Miscellaneous 
 More than one pathology 
 No abnormalities detected 

































 Odds ratio (99% CI) 
 
 1.26  (0.70 to 2.25) 
 1.19  (0.89 to 1.61) 
 0.98  (0.71 to 1.34) 
 1.30  (0.89 to 1.90) 
 1.03  (0.70 to 1.51) 
 1.03  (0.92 to 1.16) 





 Reference category 
Hearing and Vision impairment in survivors only  N (%)  
Deaf or requires hearing aids 15/551 (3) 




 Odds ratio (99% CI) 
 1.06 (0.40 to 2.79) 
 0.63 (0.21 to 1.90)  
Level of Nursing Care in survivors only   N (%)  
  N=613E N=615E Odds ratio (99% CI) 
Postnatal day 7 Level 1 323 (51) 321 (51) 1.01  (0.85 to 1.20) 
 Level 2 206 (33) 212 (34) 1.03  (0.86 to 1.23) 
 Level 3 84  (13) 82   (13) Reference category 
 N=598 N=596 
Postnatal day 14 Level 1 230 (37) 219 (35) 1.05  (0.90 to 1.22) 
 Level 2 200 (32) 230 (37) 1.15  (0.99 to 1.33) 
 Level 3 168 (27) 147 (23) Reference category 
 N=583 N=577 
Postnatal day 28 Level 1 137 (22) 131 (21) 1.01  (0.86 to 1.17) 
 Level 2 216 (34) 228 (36) 1.06  (0.93 to 1.20) 
 Level 3 230 (37) 218 (35) Reference category 
 N=564 N=569 
34 corrected weeks’ gestation Level 1 39   (6) 33   (5) 0.89  (0.69 to 1.16) 
 Level 2 188 (30) 181 (29) 0.96  (0.84 to 1.09) 
  Level 3 337 (53 355 (57) Reference category 
Parenteral nutrition as a percentage of total nutrition mean % ± SD (NF)  
In survivors only 
Postnatal day 7  57.1 ± 37.0 (613) 57.2 ± 37.2 (613) 
Postnatal day 14  23.9 ± 37.5 (597) 24.0 ± 37.0 (595) 
Postnatal day 28  13.5 ± 31.0 (575) 13.2 ± 30.6 (575) 
34 corrected weeks’ gestation 8.8 ± 26.1 (558) 8.4 ± 24.9 (565) 






 (99% CI) 
 
-5.58 to 5.36 
-5.68 to 5.46 
-4.42 to 4.95 
-3.55 to 4.30 
A  Intention-to-treat population includes: deaths & severely disabled infants which were coded 55 for the Cognitive score, 
47 for the Language composite score and 46 for the Motor composite score. Missing outcomes for losses to follow-up 
and for infants who were withdrawn but allowed their data to be used were imputed   
B  In the four Bayley-III subtest scores deaths were scored as 1 or 0, reflecting their minimum scores.   
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C  Two infants had no postnatal data collection forms 
D  The odds ratio was any cerebral pathology compared to no cerebral pathology   
E  N varies due to deaths or to infant withdrawals  
F  N varies due to deaths, infant withdrawals and missing data  
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Randomized in error 
N=2 
Withdrawn 
N=6 Data used to point 













N=6 No data used  
 
Withdrawn 
N=8 No data used  
 
Withdrawn 
N=8 Data used to point 









N=30 Ongoing data 
 collected/used
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FIGURE 2: Differences in Mean Levels of T4 and log TSH between Iodide and Placebo Groups by 
Gestation at Delivery and Day of Blood Sampling  
 
Error bars ±2 standard errors *1 p=0.03  *2 p=0.007  *3 p=0.002  *4 p=0.011    *5 p= 0.035   *6 p=0.046  
*7 p=0.033 
 
Negative numbers indicate that the iodide group had lower levels of T4 or TSH than the placebo group 
Positive numbers indicate that the iodide group had higher levels of T4 or TSH than the placebo group  
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FIGURE 3: Differences in Mean Bayley-III Scores in survivorsA between Iodide and Placebo Groups 





Statistic and p value 
 




F=4.193  P=0.041 
 
 





Statistic and p value 
 
F=4.425  P=0.036 
 
 
F=3.404  P=0.065 
 
 
F=0.376  P=0.540 
 
F=0.138  P=0.710 
 
A infants who actually had a Bayley-III assessment (i.e. excludes imputed data) 
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SECTION 1, SUPPLEMENTARY TABLES AND FIGURES 
SUPPLEMENTARY TABLE 0 Infants recruited by week of gestation 
 
Gestational age (number and %) Iodide Placebo 
22 weeks  1  (0.2%)  1  (0.2%) 
23 weeks  12  (1.9%)  14  (2.2%) 
24 weeks  49  (7.8%)   47  (7.5%) 
25 weeks  70  (11.1%)  71  (11.3%) 
26 weeks  83  (13.2%)  74  (11.8%) 
27 weeks  83  (13.2%)  91  (14.5% 
28 weeks  109  (17.3%)  115 (18.3%) 
29 weeks  112  (17.7%)  112  (17.8%) 
30 weeks  112  (17.7%)  103  (16.4%) 
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SUPPLEMENTARY TABLE 1 Definitions of Postnatal Illnesses Recorded  
Condition/illness/term  Definition  
Postnatal conditions 
Respiratory distress syndrome 
 
Requiring oxygen with or without ventilatory support 
Pneumothorax Present if air leak on chest x-ray with or without treatment 
Pulmonary interstitial emphysema Radiological changes seen 
Pulmonary haemorrhage Fresh blood in ET, thought not to be due to trauma 
Chronic lung disease Receiving supplemental oxygen at equivalent of 36 weeks’ gestation 
Cerebral pathology – closest to 34 corrected 
weeks 
• No abnormalities detected 
• Porencephalic cyst 
• Cystic periventricular leukomalacia 
• Ventriculomegaly 
• Cerebral atrophy 
Persistent ductus arteriosus Requiring treatment with any of the following: fluid restriction and diuretics 
with or without surgery or indomethacin 
Necrotizing enterocolitis Requiring treatment with TPN and ≥7 days antibiotic therapy, and/or 
surgery 
Retinopathy of prematurity Requiring treatment  
Congenital anomalies  
Hyperbilirubinaemia Requiring treatment – highest level recorded 
Meningitis Confirmed by positive culture 
Infection 
 
Symptomatic infant with positive culture of blood, cerebrospinal fluid, or 
other normally sterile site, and with haematological markers of infection 
including one or more of the following: raised CRP, high or low white blood 
cell count, thrombocytopenia 
Level of Nursing Care – The BAPMA score 
Level 1 
Ventilated babies up to 24 hours post ventilation; receiving CPAP & <5 days 
old; <1,000 grams & receiving CPAP (plus 24 hrs after withdrawal); <29 
weeks (first 48 hrs); emergency surgery pre- and post-operation (first 48 
hrs); full exchange transfusion, peritoneal dialysis, IV’s required for 
circulatory support/pulmonary vasodilator/prostaglandin (plus 24 hrs after 
withdrawal); instability requiring 1:1 care; care of the terminally ill on the 
day of death.  
Level 2 CPAP; <1,000g; TPN; convulsions; O2 therapy & <1,500g; Neonatal 
Abstinence Therapy; I/A lines/chest drains; partial exchange transfusion; 
tracheostomy care until supervised by parent; requiring frequent 
stimulation for severe apnoea.  
Level 3 Special care is provided for all other infants who could not reasonably be 
expected to be looked after at home by their mother  
A   British Association of Perinatal Medicine.  Standards for hospitals providing neonatal intensive and high dependency 
care. London: British Association of Perinatal Medicine, 2001. 
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SUPPLEMENTARY TABLE 2 Cause of Death during the Intervention Phase of the Trial 
Event (number and %) Iodide Placebo 
Congenital anomalyA  0  0 
Pulmonary immaturityB  3 (5)  3 (5) 
Hyaline membrane diseaseC  0  2 (3) 
Hyaline membrane disease with intraventricular 
haemorrhage or infarctionC 
 
 6 (10) 
 
 3 (5) 
Hyaline membrane disease with infectionC  2 (3)  1 (2) 
Intraventricular haemorrhageD   3 (5)  4 (7) 
InfectionE  14 (23)  12 (20) 
Necrotizing enterocolitis  19 (31)  18 (31) 
Late sequelae of ventilationF  1 (2)  2 (3) 
Miscellaneous  13 (21)  14 (24) 
TotalG  61  (9.7%)  59(9.4%) 
A Congenital Anomaly: any genetic or structural defect arising at conception or during embryogenesis incompatible with life 
or potentially treatable but causing death. 
B Pulmonary Immaturity: structural immaturity of the lung so gross as to render sustained ventilatory support 
unsatisfactory from the outset. 
CHyaline membrane disease (HMD): death due to pulmonary immaturity or surfactant deficiency. Specify if there was co-
existing significant periventricular or intraventricular bleeding (or infarction) or secondary infection. 
DIntracranial haemorrhage: deaths due to intraventricular and periventricular haemorrhage should be separated from 
those due to other intracerebral haemorrhage (such as subdural and subarachnoid bleeding). Exclude intraventricular and 
periventricular haemorrhage associated with significant HMD. 
EInfection: include antepartum and postpartum infection, but if there was infection associated with severe HMD, record 
this as defined previously. 
FLate sequelae of ventilation: death due to progressive respiratory failure after one week of age without an acute 
precipitating cause. This should include babies dying with classic bronchopulmonary dysplasia after 28 days.  
GThe numbers of deaths in this table are those recorded during the intervention phase of the trial; the numbers are lower 
than those shown in Figure 1 of the paper as that figure includes deaths which occurred between the end of the 
intervention phase and the two year follow up.  
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SUPPLEMENTARY TABLE 3a Unadjusted and Adjusted Analyses of Primary and Secondary 
Outcomes: Difference in Bayley Scores between the Iodide compared to the Placebo group in 
Surviving Infants (N=498 iodide, N=499 placebo group)  
OUTCOMES  UNADJUSTED (SCORES (95% CI) ADJUSTED SCORESA (95% CI) 
Primary outcomes   
Cognitive score -0.67 (-2.62 to 1.28) -0.60 (-2.49 to 1.29) 
Motor composite score -0.14 (-2.07 to 1.79) -0.04 (-1.87 to 1.80) 
Language composite score -0.42 (-2.62 to 1.78) -0.38 (-2.50 to 1.74) 
Secondary Outcomes Unadjusted scores (99% CI) Adjusted scoresA (99% CI) 
Expressive communication scaled score -0.13 (-0.66 to 0.40) -0.10 (-0.62 to 0.41) 
Receptive communication scaled score -0.03 (-0.54 to 0.49) -0.03 (-0.53 to 0.47) 
Fine motor scaled score 0.08 (-0.42 to 0.58) 0.12 (-0.35 to 0.60) 
Gross motor scaled score -0.16 (-0.60 to 0.28) -0.16 (-0.59 to 0.27) 
Aadjusted for the factors used at minimisation (i.e. infant gender, centre of randomization, gestation at delivery) and 
Bayley assessor 
SUPPLEMENTARY TABLE 3b Unadjusted and Adjusted Analyses of Primary and Secondary 
Outcomes: Difference in Bayley Scores between the Iodide compared to the Placebo group in 
Surviving Infants, excluding those with additional exposure to iodide (N=468 iodide group, N=469 
placebo) 
OUTCOMES  UNADJUSTED SCORES (95% CI) ADJUSTED SCORESA (95% CI) 
Primary outcomes   
Cognitive score -0.69 (-2.67 to 1.28) -0.65 (-2.56 to 1.27) 
Motor composite score -0.41 (-2.34 to 1.52) -0.39 (-2.23 to 1.46) 
Language composite score -0.20 (-2.45 to 2.04) -0.25 (-2.43 to 1.93) 
Secondary Outcomes Unadjusted scores (99% CI) Adjusted scoresA (99% CI) 
Expressive communication scaled score -0.07 (-0.61 to 0.47) -0.06 (-0.59 to 0.47) 
Receptive communication scaled score -0.01 (-0.53 to 0.52) -0.03 (-0.54 to 0.49) 
Fine motor scaled score 0.05 (-0.45 to 0.56) 0.07 (-0.41 to 0.55) 
Gross motor scaled score -0.22 (-0.66 to 0.22) -0.23 (-0.66 to 0.21) 
Aadjusted for the factors used at minimisation (i.e. infant gender, centre of randomization, gestation at delivery) and 
Bayley assessor 
SUPPLEMENTARY TABLE 3c Unadjusted and Adjusted Analyses of Primary and Secondary 
Outcomes: Difference in Bayley Scores between the Iodide compared to the Placebo group in all 
Randomized InfantsA (N=631 iodide group, N=628 placebo) 
Outcomes UNADJUSTED SCORES (95% CI) ADJUSTED SCORESB (95% CI) 
Primary outcomes   
Cognitive score -0.34 (-2.56 to 1.89) -0.36 (-2.39 to 1.68) 
Motor composite score 0.21 (-2.23 to 2.64) 0.22 (-1.98 to 2.43) 
Language composite score -0.05 (-2.48 to 2.39) -0.07 (-2.32 to 2.17) 
Secondary Outcomes Unadjusted scores (99% CI) Adjusted scoresB (99% CI) 
Expressive communication scaled score -0.02 (-0.62 to 0.57) -0.01 (-0.56 to 0.53) 
Receptive communication scaled score 0.05 (-0.51 to 0.61) 0.04 (-0.49 to 0.57) 
Fine motor scaled score 0.15 (-0.47 to 0.76) 0.16 (-0.41 to 0.72) 
Gross motor scaled score -0.09 (-0.63 to 0.45) -0.10 (-0.60 to 0.40) 
A i.e. by intention to treat which includes survivors, deaths, too disabled for assessment and lost to follow up 
Badjusted for the factors used at minimisation (i.e. infant gender, centre of randomization, gestation at delivery) and Bayley 
assessor 
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SUPPLEMENTARY TABLE 3d Unadjusted Analysis of the Primary and Secondary Outcomes showing 
the Mean, and Differences between the Mean, of the Bayley-III Scores for Infants who Attended 
for Assessment and Including Single Imputation for Deaths and Disabled Infants  








95% CI (P value) 
Primary outcomes (mean ± SD, n) 
Bayley-III Cognitive score 88.2 ± 19.4 (572) 
Bayley-III Motor composite score 87.6 ± 21.4 (571) 
Bayley-III Language composite score 84.6 ± 22.0 (572) 
  
 88.7 ± 19.8 (576) 
 87.5 ± 22.0 (576) 






 -2.69 to 1.85 (0.72) 
 -2.44 to 2.59 (0.95) 
 -2.71 to 2.40 (0.90) 
Secondary outcomes (mean ± SD, n)  
Bayley-III subtests 
 Receptive language 7.40 ± 3.85 (572) 7.39 ± 3.82 (574) 0.01 
Expressive language 7.17 ± 4.11 (572) 7.24 ± 4.13 (573) -0.07 
Fine motor 8.73 ± 4.05 (571) 8.62 ± 4.21 (575) 0.11 
 Gross motor 6.97 ± 3.69 (572) 7.07 ± 3.74 (575) -0.10 
 99% CI  
 
 -0.57 to 0.60  
 -0.70 to 0.56 
 -0.52 to 0.74  
 -0.67 to 0.47  
Low Bayley score in any main domain (cognitive, motor, language) 
(number and %)  
≥ 85 286 (50) 301 (52) 
<85 (or death) 286 (50) 275 (48) 
 Odds ratio (99% CI) 
 
1.10 (0.81 to 1.48) 
 
SUPPLEMENTARY TABLE 3e Unadjusted Analysis of the Primary and Secondary Outcomes showing 
the Mean, and Differences between the Mean, of the Bayley-III Scores for Infants who Attended 
for Assessment (Excluding Single Imputation for Deaths and Disabled Infants)  





(Iodide – placebo) 
95% CI (P value) 
Primary outcomes (mean ± SD, n) 
Bayley-III Cognitive score 93.2 ± 15.6 (498) 
Bayley-III Motor composite score 93.8 ± 15.1 (497) 
Bayley-III Language composite score 90.2 ± 17.7 (498) 
  
 93.8 ± 15.8 (499) 
 93.9 ± 15.9 (499) 






-2.62 to 1.28 (0.50) 
-2.07 to 1.79 (0.89) 
-2.62 to 1.78 (0.71) 
Secondary outcomes (mean ± SD, n)  
Bayley-III subtests 
 Receptive language 8.35 ± 3.17 (498) 8.38 ± 3.09 (497) -0.03 
Expressive language 8.24 ± 3.26 (498) 8.37 ± 3.21 (498) -0.13 
Fine motor 9.89 ± 2.93 (497) 9.80 ± 3.17 (498) -0.08 
 Gross motor 8.00 ± 2.71 (498) 8.16 ± 2.69 (498) -0.16 
 99% CI  
  
-0.54 to 0.49  
-0.66 to 0.40  
-0.42 to 0.58  
-0.60 to 0.28  
Low Bayley score in any main domain (cognitive, motor, language) 
(number and %)  
≥ 85 286 (57) 301 (60) 
<85  212 (43) 198 (40) 
 Odds ratio (99% CI) 
 
1.13 (0.81 to 1.57) 
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SUPPLEMENTARY TABLE 4  Comparison of Prescribed Drug Usage between the Iodide and the 
Placebo Supplemented Group 
 Iodide Placebo Odds ratio (99%) 
 Yes/No Yes/No 
 
Day 7 postnatal n=613 n=615  
Dexamethasone 3/610 2/613 1.51 (0.14 to 15.90) 
Morphine/Diamorphine 83/530 81/534 1.03 (0.67 to 1.59) 
Caffeine 501/112 498/117 1.05 (0.72 to 1.53) 
Dopamine 27/586 20/595 1.37 (0.63 to 2.97) 
Metronidazole 30/583 34/581 0.88 (0.45 to 1.71) 
Dobutamine 13/600 15/600 0.87 (0.32 to 2.33) 
Indomethacin 4/609 6/609 0.67 (0.13 to 3.54) 
Day 14 postnatal n=597 n=596  
Dexamethasone 4/593 2/594 2.00 (0.21 to 18.74) 
Morphine/Diamorphine 62/535 58/538 1.08 (0.66 to 1.77) 
Caffeine 484/113 483/113 1.00 (0.69 to 1.47) 
Dopamine 9/588 8/588 1.13 (0.32 to 3.97) 
Metronidazole 31/566 23/573 1.36 (0.66 to 2.82) 
Dobutamine 6/591 4/592 1.50 (0.28 to 7.98) 
Indomethacin 3/594 4/592 0.75 (0.10 to 5.38) 
Day 28 postnatal n=582 n=578  
Dexamethasone 18/564 27/551 0.65 (0.29 to 1.45) 
Morphine/Diamorphine 43/539 48/530 0.88 (0.50 to 1.55) 
Caffeine 384/198 393/185 0.91 (0.66 to 1.26) 
Dopamine 7/575 4/574 1.75 (0.35 to 8.84) 
Metronidazole 22/560 23/555 0.95 (0.43 to 2.08) 
Dobutamine 3/579 3/575 0.99 (0.12 to 8.18) 
Indomethacin 2/580 0/578 - 
34 weeks equivalent gestational age n=564 n=569  
Dexamethasone 10/554 13/556 0.77 (0.26 to 2.31) 
Morphine/Diamorphine 19/545 13/556 1.49 (0.58 to 3.82) 
Caffeine 306/258 297/272 1.09 (0.80 to 1.48) 
Dopamine 4/560 2/567 2.03 (0.22 to 18.95) 
Metronidazole 15/549 8/561 1.92 (0.61 to 5.98) 
Dobutamine 1/563 1/568 1.01 (0.03 to 38.66) 
Indomethacin 0/564 0/569 - 
Change in denominator (n) is due to deaths, infants withdrawn, infants discharged home or missing data. 
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SUPPLEMENTARY TABLE 5  Hypothyroxinaemic statusA and Bayley-III scores in survivors: mean ± 
standard deviation, (n)B   
Sub-group   Bayley-III main domain scores 
Cognitive  Motor   Language 
 Bayley-III subset scores 
Receptive Expressive  Fine Gross 
language language  motor motor 
Euthyroid  group 
 iodide 
 placebo 
T-test Iodide Versus 
Placebo   p value α 99% 
 
94 ± 16 (389) 
95 ± 15 (400) 
  ns 
 
94 ± 15 (388) 
95 ± 15 (400) 
  ns 
 
91 ± 18 (389) 
92 ± 17 (399) 
  ns 
 
8.4 ± 3 (389) 
8.7 ± 3 (399) 
  ns 
 
8.3 ± 3 (389) 
8.6 ± 3 (398) 
  ns 
 
 10.0 ± 3 (388) 
 9.9 ± 3 (399) 
 ns 
 
8.1 ± 3 (389) 
8.3 ± 3 (400) 




T-test Iodide Versus 
Placebo   p value α 99% 
 
92 ± 15 (107) 
89 ± 18 (97)
 ns 
 
92 ± 15 (107) 
91 ± 19 (97) 
 ns 
 
89 ± 18 (17) 
85 ± 19 (96) 
 ns 
 
8.1 ± 3 (107) 
7.3 ± 3 (96)  
ns 
 
8.1 ± 4 (107) 
7.4 ± 3 (96)  
 ns 
 
 9.7 ± 3 (107) 
 9.3 ± 4 (97) 
 ns 
 
7.6 ± 3 (107) 
7.7 ± 3 (96) 
 ns 
 
A Infant thyroxinaemic status was classified as hypothyroxinaemia - a T4 level at or below the 10th percentile, corrected 
to gestational age subgroup (i.e =<25, 26-27, 28-30 weeks) on postnatal days 7, 14 or 28; euthyroid constituted the 
remainder 
B  This is a subgroup analysis, which was specified in the Statistical Analysis Plan                           
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SUPPLEMENTARY TABLE 6 Trial Safety, SUSARs and Adverse Events 
Event  Iodide Placebo 
SUSARs  0  0 
ADVERSE EVENTS 
• Incorrectly reported as a SAE 
• TSH levels ≥6 mU/l identified on blood spot cards 
 Hypothyroidism  
(specific diagnosis of congenital or transient hypothyroidism given OR 
no diagnosis mentioned but treated with levo-thyroxine) 
 Hypopituitarism   
 Thyroid function monitored 
(or local endocrine policy followed) 
• Miscellaneous 
(e.g. persistent metabolic acidosis, fluctuating sodium levels, 
intrahepatic calcification, hypernatremia, fulminating NEC, GI 
obstruction, abdominal mass, pleural effusion, clot in aorta, aortic 
sleeve thrombus, hypoglycemia) 
































A Includes two cases of hyperthyroidism although TFTs indicative of hypothyroidism 
 
The differences between the numbers in the intervention arm versus the placebo arm which reported hypothyroidism i.e. 
12 versus 2, is statistically significant (Fisher Exact p=0.01).  (The difference between the numbers who had TFTs monitored 
i.e. 33 versus 19 is not statistically significant.)  This table reports adverse events that were reported to the trial team 
during the active phase of the trial (i.e. when infants were taking trial solutions).  We encouraged a low threshold for 
reporting potential thyroid dysfunction.  The thyroid hormone at which units started T4 replacement therapy was highly 
variable.  
 
We followed up all infants who had a reported adverse event and during the neonatal period 11 infants were treated with 
Levo-thyroxine and received a conditional diagnosis of hypothyroidism; the numbers receiving Levo-thyroxine were 9 in 
the iodine arm and 2 in the placebo, Fisher Exact p=0.07.   
 
The highest TSH level recorded was an isolated value of 34 mU/L. 
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SUPPLEMENTARY FIGURE 1 Difference in Mean Levels of TBG between Iodide and Placebo Groups 




Error bars are ±2 standard errors of the mean 
 
Negative numbers indicate that the iodide group had lower levels of TBG than the placebo group 
Positive numbers indicate that the iodide group had higher levels of TBG than the placebo group 
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SUPPLEMENTARY FIGURE 2 Difference in Mean Bayley-III Scores in SurvivorsA Between the Iodide 
and Placebo Groups by Gestational Sub-group and Maternal Thyroid Status 
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SUPPLEMENTARY FIGURE 2 Difference in Mean Bayley-III Scores in SurvivorsA Between the Iodide 




Statistic and p value 
 
 
F=0.780  P=0.458 
 
 
F=0.334  P=0.564 
 
 

























F=0.945  P=0.389 
 
 





F=0.247  P=0.781 
 
 








F=0.539  P=0.463 
 
 
number of women with thyroid disease iodide placebo 
yes 22 19 
no 609 609 




SUPPLEMENTARY FIGURE 3a Difference in Mean Bayley-III Scores in survivorsA Between the Iodide 
and Placebo Groups, by Pre-specified Sub-group Analyses: Main Domains of the Bayley-III 
 
Interaction 































F=0.297  P=0.743 
 
Interaction 







































































Bars represent 95% confidence intervals 
 
A i.e. infants who actually had a Bayley-III 
assessment completed (excludes imputed data). 
 
 
Negative scores indicate that the Iodide group performed worse than placebo group, positive scores that they performed better 
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SUPPLEMENTARY FIGURE 3b Difference in Mean Bayley-III Scores in SurvivorsA Between the Iodide 
and Placebo Groups, by Pre-specified Sub-group Analyses: Subtest Domains of the Bayley-III 
 
Interaction 

























































































































F=0.895  P=0.409 
Negative scores indicate that the Iodide group performed worse than placebo group, positive scores that they performed better 
A i.e. infants who actually had a Bayley-III assessment completed (excludes imputed data). 
 
Footnote to Supplementary Figure 3a and 3b.  Care levels are a proxy for illness severity9 (see Supplementary table 1 for definition).   
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SECTION 2, SAMPLE SIZE CALCULATION AND HANDLING OF MISSING BAYLEY-III OUTCOME SCORES 
 
Sample Size Calculation 
Assumptions: 
• Bayley-III scores with mean = 100, sd=15 
• 19% deaths and severe disability each assigned a Bayley-III score of 40 
 
Then 
• overall expected mean is M0 = .19*40+.81*100 = 88.6 
• Variance 19*(40-mo)2 + .81*(100-mo) 2+.81*152 = 736.29; sd = (27.132) 
• If intervention increases mean in survivors to 106, then overall expected mean=93.46, variance 852.64 sd 
(27.132) 
• with n=700 per group, the expected difference in means =93.46 – 88.6 = 4.86 power; stand error = 1.51, SE 
assuming no effect = 1.45 
• Power 91%, p0.05 
 
Missing primary outcomes 
The primary outcome is the Bayley-III Scores. These scores might be missing under certain circumstances: 
1. If the infant dies before neurodevelopmental assessment, they were recorded as a score of 55 in the cognitive 
domain, 46 in the motor domain and 47 in the language domain (the minimum score for each scale). 
 
2. If an infant failed to complete an assessment that has been started they were scored according to what they 
have done plus a fail recorded for all items following their refusal to carry on. A minimum score of 65 was set. 
 
3. Infants who were unable to be assessed because of severe neurodevelopment disability were scored 55 in the 
cognitive domain, 46 in the motor domain and 47 in the language domain (the minimum score for each scale). 
 
4. Neurodevelopment scores were imputed for infants who were untraceable or whose mothers refused to take 
part in an assessment, provided such refusal was not the result of disability – in which case point 3 applied.  
Following the Statistical Analysis Plan, the scores were imputed from gestational age, BAPM level and 
hypothyroxinaemic status recorded for other infants in the trial; however, we also added neurodevelopmental 
assessor, infant gender and randomisation centre. Multiple imputation was used.   
 
5. Hypothyroxinemic status on day 14 was selected as the blood collection day to determine the imputation 
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SECTION 3,   TRIAL PROCEDURES 
1. No infant’s allocation was unblinded during the trial; neither during the intervention phase, during the 
assessment phase, nor during analysis. 
2. Protocol violations/deviations 
There were no protocol violations. There were three groups of protocol deviation 
• Procedural errors –these were primarily reported with errors concerning the daily trial solutions; there 
were very few other procedural errors (Supplementary Table 7) 
• Infant exposures to additional iodide – all infants exposed to additional iodide, such as via contrast 
media or topical iodide used for skin cleansing, were withdrawn from trial solutions and had thyroid 
function monitored (following a trial guidance sheet). During the intervention phase of the trial 79 infants 
were withdrawn from the trial solutions due to exposure to additional iodide. Of the exposed infants two 
were found to have transient thyroid dysfunction. 
• Neurodevelopmental assessment – for the I2S2 trial the Bayley-III should be completed at 2 years of age 
corrected for prematurity plus or minus one month. Of the 997 tests undertaken 112 (22%) were outwith 
this window for the iodide supplemented group and 115 (23%) for the placebo group (Supplementary 
Table 8). The Bayley-III scores are standardized for age and the inclusion of such infants does not 
invalidate the outcome.  
SUPPLEMENTARY TABLE 7 Proportion of Infants Receiving Expected Number of Daily Trial 
Solutions  
Daily trial solutions Iodide Placebo 
Total infants at intervention stage  N=631  N=628 
Number of infants who had a missed dose recorded  209 (33.1%)  188 (29.9%) 
Number of infants receiving no solutionsA  3  (0.5%)  4 (0.6%) 
Number of infants who received the trial solution on correct day ±1 dayB  545 (86.4%)  544 (86.6%) 
Number of infants who received the trial solution on correct day ±2 daysB  64 (10.1%)  67 (10.6%) 
Number of infants who received the trial solution on correct day ± 3+ daysB  19 (3.0%)  13 (2.2%) 
A i.e. infants either died or withdrew before trial solutions were started 
B ± days taking into account number of days on trial solution plus missed doses recorded; time of trial solutions final dose 
not recorded, incomplete daily logs with missing information 
SUPPLEMENTARY TABLE 8 Number of Infants Completing the Bayley-III Assessment within and 
outwith the Recommended Time of 2 years corrected for prematurity ± 30 days 
 Iodide Placebo 
    
Total Infants completing Bayley III assessment    N=498  N=499 
Infants seen ± 30 days i.e. according to Bayley-III 
recommendation 
  
 386  (78%) 
 
 384 (77%) 
Infants seen ± 37 days   28 (6%)  33 (7%) 
Infants seen ± 2 months   32 (6%)  32 (6%) 
Infants seen ± 3 months   26 (5%)  24 (5%) 
Infants seen ± 4–6 months   19 (4%)  22 (4%) 
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SUPPLEMENTARY TABLE 9 Loss to Follow-up According to Stage of the Trial  
 Iodide  Placebo  
Total Infants Randomised N=1,275   
Infants randomised in error  2   
Intervention stage N=1,273  N=637  N=636 
Consent withdrawn: No data used A   6   8 
Consent withdrawn: Data used to point of withdrawal   2  4 
Withdrawn from solutions Ongoing data collected and 
follow up undertaken: 
 Exposure to iodide 
 Parental wish 
 Maternal iodide supplementation 
 Raised TSH on trial blood spot card 
 Raised TSH – jaundice screen 
 Maternal/fetal Graves’ disease 
 
 Total 




















Deaths   61  59 
Follow up Stage N=1,133  N=568  N=565 
Consent withdrawn: Data used to point of withdrawal   4  4 
DeathsB   4  7 
Severely disabled   9  11 
Lost to follow up   53  44 
2 year follow up Bayley-III assessment completed   498  499 
Primary analysis (under intention-to-treat) N=1,259  N=631  N=628 
A Numbers not included for Primary analysis (under intention-to-treat) 
B Causes of death unknown 
 
 
